Kymera Therapeutics (NASDAQ:KYMR) Reaches New 12-Month Low – Time to Sell?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price reached a new 52-week low on Monday . The company traded as low as $26.99 and last traded at $28.23, with a volume of 32523 shares. The stock had previously closed at $29.62.

Analyst Upgrades and Downgrades

KYMR has been the subject of several research reports. BTIG Research started coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 target price for the company. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $38.00 to $57.00 in a report on Monday, December 2nd. BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price target on the stock. Finally, Stephens restated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Kymera Therapeutics Stock Down 7.0 %

The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -11.76 and a beta of 2.22. The company has a fifty day moving average price of $35.86 and a two-hundred day moving average price of $41.75.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,788 shares of company stock valued at $455,202 over the last quarter. Company insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. raised its position in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares during the last quarter. State of Wyoming acquired a new position in Kymera Therapeutics in the 4th quarter valued at $45,000. GF Fund Management CO. LTD. purchased a new position in shares of Kymera Therapeutics during the 4th quarter worth $55,000. KBC Group NV boosted its holdings in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Kymera Therapeutics in the third quarter valued at $95,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.